{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:59:24Z","timestamp":1789009164642,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1038\/s41375-021-01246-w","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T08:12:40Z","timestamp":1618301560000},"page":"3245-3256","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer"],"prefix":"10.1038","volume":"35","author":[{"given":"Deepak","family":"Singhal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5105-2554","authenticated-orcid":false,"given":"Christopher N.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9996-4277","authenticated-orcid":false,"given":"Simone","family":"Feurstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li Yan A.","family":"Wee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6699-5336","authenticated-orcid":false,"given":"Luke","family":"Moma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2315-091X","authenticated-orcid":false,"given":"Monika M.","family":"Kutyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakchha","family":"Chhetri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Eshraghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9081-3405","authenticated-orcid":false,"given":"Andreas W.","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul P-S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Babic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy T.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6957-8423","authenticated-orcid":false,"given":"Sarah","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soma","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swetansu","family":"Pattnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9023-0138","authenticated-orcid":false,"given":"Anna L.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"D\u2019Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola K.","family":"Poplawski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5813-631X","authenticated-orcid":false,"given":"Hamish S.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1914-9158","authenticated-orcid":false,"given":"Lucy A.","family":"Godley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devendra K.","family":"Hiwase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,13]]},"reference":[{"key":"1246_CR1","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nature12981","volume":"505","author":"N Rahman","year":"2014","unstructured":"Rahman N. Realizing the promise of cancer predisposition genes. Nature. 2014;505:302\u20138.","journal-title":"Nature"},{"key":"1246_CR2","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1182\/blood-2016-01-583625","volume":"127","author":"R Peffault de Latour","year":"2016","unstructured":"Peffault de Latour R, Soulier J. How I treat MDS and AML in Fanconi anemia. Blood. 2016;127:2971\u20139.","journal-title":"Blood"},{"key":"1246_CR3","doi-asserted-by":"publisher","unstructured":"Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. NCCN clinial practice guidelines in Oncology: National Comprehensive Cancer Network; 2020;18. https:\/\/doi.org\/10.6004\/jnccn.2020.0017.","DOI":"10.6004\/jnccn.2020.0017"},{"key":"1246_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cell.2018.03.039","volume":"173","author":"KL Huang","year":"2018","unstructured":"Huang KL, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, et al. Pathogenic germline variants in 10,389 adult cancers. Cell. 2018;173:355\u201370.","journal-title":"Cell"},{"key":"1246_CR5","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa1508054","volume":"373","author":"J Zhang","year":"2015","unstructured":"Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, et al. Germline mutations in predisposition genes in pediatric cancer. N Engl J Med. 2015;373:2336\u201346.","journal-title":"N Engl J Med"},{"key":"1246_CR6","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"1246_CR7","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/cncr.29615","volume":"122","author":"J Churpek","year":"2016","unstructured":"Churpek J, Marquez R, Neistadt B, Claussen K, Lee M, Churpek M, et al. Inherited mutations in cancer susceptibility genes are common among breast cancer survivors who develop therapy-related leukemia. Cancer. 2016;122:304\u201311.","journal-title":"Cancer"},{"key":"1246_CR8","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/jmedgenet-2011-100674","volume":"49","author":"E Schulz","year":"2012","unstructured":"Schulz E, Valentin A, Ulz P, Beham-Schmid C, Lind K, Rupp V, et al. Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms. J Med Gen. 2012;49:422\u20138.","journal-title":"J Med Gen"},{"key":"1246_CR9","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1182\/blood.V114.22.1102.1102","volume":"114","author":"MG Martin","year":"2009","unstructured":"Martin MG, Jacoby M, Shao J, Deych E, Graubert T, Walter MJ. BRCA1 and BRCA2 nucleotide variants in young women with therapy related acute myeloid leukemia. Blood. 2009;114:1102.","journal-title":"Blood"},{"key":"1246_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.44","volume":"5","author":"MT Voso","year":"2015","unstructured":"Voso MT, Fabiani E, Zang Z, Fianchi L, Falconi G, Padella A, et al. Fanconi anemia gene variants in therapy-related myeloid neoplasms. Blood Cancer J. 2015;5:e323.","journal-title":"Blood Cancer J"},{"key":"1246_CR11","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/leu.2017.28","volume":"31","author":"L Guidugli","year":"2017","unstructured":"Guidugli L, Johnson AK, Alkorta-Aranburu G, Nelakuditi V, Arndt K, Churpek JE, et al. Clinical utility of gene panel-based testing for hereditary myelodysplastic syndrome\/acute leukemia predisposition syndromes. Leukemia. 2017;31:1226\u20139.","journal-title":"Leukemia"},{"key":"1246_CR12","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1038\/s41375-019-0479-8","volume":"33","author":"D Singhal","year":"2019","unstructured":"Singhal D, Wee LYA, Kutyna MM, Chhetri R, Geoghegan J, Schreiber AW, et al. The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution. Leukemia. 2019;33:2842\u201353.","journal-title":"Leukemia"},{"key":"1246_CR13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201323.","journal-title":"Genet Med"},{"key":"1246_CR14","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1200\/JCO.2014.59.5728","volume":"33","author":"G Bougeard","year":"2015","unstructured":"Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fermey P, Belotti M, et al. Revisiting li-fraumeni syndrome from TP53 mutation carriers. J Clin Oncol. 2015;33:2345\u201352.","journal-title":"J Clin Oncol"},{"key":"1246_CR15","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1182\/blood-2015-10-676098","volume":"127","author":"M Lewinsohn","year":"2016","unstructured":"Lewinsohn M, Brown AL, Weinel LM, Phung C, Rafidi G, Lee MK, et al. Novel germ line DDX41 mutations define families with a lower age of MDS\/AML onset and lymphoid malignancies. Blood. 2016;127:1017\u201323.","journal-title":"Blood"},{"key":"1246_CR16","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.ccell.2015.03.017","volume":"27","author":"C Polprasert","year":"2015","unstructured":"Polprasert C, Schulze I, Sekeres MA, Makishima H, Przychodzen B, Hosono N, et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell. 2015;27:658\u201370.","journal-title":"Cancer Cell"},{"key":"1246_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1182\/blood.2019000937","volume":"136","author":"AL Brown","year":"2020","unstructured":"Brown AL, Hahn CN, Scott HS. Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA). Blood. 2020;136:24\u201335.","journal-title":"Blood"},{"key":"1246_CR18","doi-asserted-by":"publisher","unstructured":"Feurstein S, Churpek JE, Walsh T, Keel S, Hakkarainen M, Schroeder T, et al. Germline variants drive myelodysplastic syndrome in young adults. Leukemia. 2021. https:\/\/doi.org\/10.1038\/s41375-021-01137-0","DOI":"10.1038\/s41375-021-01137-0"},{"key":"1246_CR19","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1182\/blood.2019000909","volume":"134","author":"M S\u00e9bert","year":"2019","unstructured":"S\u00e9bert M, Passet M, Raimbault A, Rahm\u00e9 R, Raffoux E, Sicre de Fontbrune F, et al. Germline DDX41 mutations define a significant entity within adult MDS\/AML patients. Blood. 2019;134:1441\u20134.","journal-title":"Blood"},{"key":"1246_CR20","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1182\/blood-2018-07-861070","volume":"132","author":"P Galera","year":"2018","unstructured":"Galera P, Hsu AP, Wang W, Droll S, Chen R, Schwartz JR, et al. Donor-derived MDS\/AML in families with germline GATA2 mutation. Blood. 2018;132:1994\u20138.","journal-title":"Blood"},{"key":"1246_CR21","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2016.310","volume":"31","author":"G Berger","year":"2017","unstructured":"Berger G, van den Berg E, Sikkema-Raddatz B, Abbott KM, Sinke RJ, Bungener LB, et al. Re-emergence of acute myeloid leukemia in donor cells following allogeneic transplantation in a family with a germline DDX41 mutation. Leukemia. 2017;31:520\u20132.","journal-title":"Leukemia"},{"key":"1246_CR22","doi-asserted-by":"publisher","first-page":"5257","DOI":"10.1182\/blood-2010-12-326322","volume":"117","author":"H Xiao","year":"2011","unstructured":"Xiao H, Shi J, Luo Y, Tan Y, He J, Xie W, et al. First report of multiple CEBPA mutations contributing to donor origin of leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood. 2011;117:5257\u201360.","journal-title":"Blood"},{"key":"1246_CR23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/bmt.2010.65","volume":"46","author":"AC Dietz","year":"2011","unstructured":"Dietz AC, Orchard PJ, Baker KS, Giller RH, Savage SA, Alter BP, et al. Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita. Bone Marrow Transpl. 2011;46:98\u2013104.","journal-title":"Bone Marrow Transpl"},{"key":"1246_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/17474086.2016.1268048","volume":"10","author":"CL Ebens","year":"2017","unstructured":"Ebens CL, MacMillan ML, Wagner JE. Hematopoietic cell transplantation in Fanconi anemia: current evidence, challenges and recommendations. Expert Rev Hematol. 2017;10:81\u201397.","journal-title":"Expert Rev Hematol"},{"key":"1246_CR25","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1002\/humu.23626","volume":"39","author":"AN Abou Tayoun","year":"2018","unstructured":"Abou Tayoun AN, Pesaran T, DiStefano MT, Oza A, Rehm HL, Biesecker LG, et al. Recommendations for interpreting the loss of function PVS1 ACMG\/AMP variant criterion. Hum Mutat. 2018;39:1517\u201324.","journal-title":"Hum Mutat"},{"key":"1246_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0690-2","volume":"12","author":"SE Brnich","year":"2019","unstructured":"Brnich SE, Abou Tayoun AN, Couch FJ, Cutting GR, Greenblatt MS, Heinen CD, et al. Recommendations for application of the functional evidence PS3\/BS3 criterion using the ACMG\/AMP sequence variant interpretation framework. Genome Med. 2019;12:3.","journal-title":"Genome Med"},{"key":"1246_CR27","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1136\/jmg.2009.073429","volume":"47","author":"MW Ruijs","year":"2010","unstructured":"Ruijs MW, Verhoef S, Rookus MA, Pruntel R, van der Hout AH, Hogervorst FB, et al. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet. 2010;47:421\u20138.","journal-title":"J Med Genet"},{"key":"1246_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/jmg.38.1.43","volume":"38","author":"A Chompret","year":"2001","unstructured":"Chompret A, Abel A, Stoppa-Lyonnet D, Brugieres L, Pages S, Feunteun J, et al. Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet. 2001;38:43\u20137.","journal-title":"J Med Genet"},{"key":"1246_CR29","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1200\/JCO.2009.22.7967","volume":"27","author":"J Tinat","year":"2009","unstructured":"Tinat J, Bougeard G, Baert-Desurmont S, Vasseur S, Martin C, Bouvignies E, et al. 2009 Version of the Chompret Criteria for Li Fraumeni Syndrome. J Clin Oncol. 2009;27:e108\u20139.","journal-title":"J Clin Oncol"},{"key":"1246_CR30","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/sj.onc.1201041","volume":"14","author":"JM Varley","year":"1997","unstructured":"Varley JM, Thorncroft M, McGown G, Appleby J, Kelsey AM, Tricker KJ, et al. A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li\u2013Fraumeni patients carrying a mutation to the TP53 gene. Oncogene. 1997;14:865\u201371.","journal-title":"Oncogene"},{"key":"1246_CR31","first-page":"987","volume":"7","author":"S Srivastava","year":"1992","unstructured":"Srivastava S, Tong YA, Devadas K, Zou ZQ, Sykes VW, Chen Y, et al. Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared \u2018second hit\u2019 on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome. Oncogene. 1992;7:987\u201391.","journal-title":"Oncogene"},{"key":"1246_CR32","doi-asserted-by":"publisher","first-page":"7825","DOI":"10.1073\/pnas.88.17.7825","volume":"88","author":"AK Metzger","year":"1991","unstructured":"Metzger AK, Sheffield VC, Duyk G, Daneshvar L, Edwards MS, Cogen PH. Identification of a germ-line mutation in the p53 gene in a patient with an intracranial ependymoma. Proc Natl Acad Sci USA. 1991;88:7825\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1246_CR33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.6004\/jnccn.2017.0003","volume":"15","author":"MB Daly","year":"2016","unstructured":"Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S, et al. NCCN guidelines insights: genetic\/familial high-risk assessment: breast and ovarian, version 2.2017. J Natl Compr Canc Netw. 2016;15:9\u201320.","journal-title":"J Natl Compr Canc Netw"},{"key":"1246_CR34","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.6004\/jnccn.2019.0044","volume":"17","author":"S Gupta","year":"2019","unstructured":"Gupta S, Provenzale D, Llor X, Halverson AL, Grady W, Chung DC, et al. NCCN guidelines insights: genetic\/familial high-risk assessment: colorectal, version 2.2019. J Natl Compr Canc Netw. 2019;17:1032\u201341.","journal-title":"J Natl Compr Canc Netw"},{"key":"1246_CR35","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1086\/340847","volume":"70","author":"M Tartaglia","year":"2002","unstructured":"Tartaglia M, Kalidas K, Shaw A, Song X, Musat DL, van der Burgt I, et al. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet. 2002;70:1555\u201363.","journal-title":"Am J Hum Genet"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01246-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01246-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01246-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T07:11:02Z","timestamp":1635318662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01246-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,13]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1246"],"URL":"https:\/\/doi.org\/10.1038\/s41375-021-01246-w","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,13]]},"assertion":[{"value":"28 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"LAG receives royalties from UptoDate, Inc. for a co-authored article on inherited predisposition to hematopoietic malignancies. HSS\u2014received honoraria from Celgene.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}